Achievements of the Belgian Antibiotic Policy Coordination Committee (BAPCOC)

H Goossens (herman.goossens@uza.be), S Coenen, M Costers, S De Corte, A De Sutter, B Gordts, I Lauzier, M. J. Struelens
1. Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
2. Department of General Practice, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
3. Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium
4. Department of General Practice, University of Ghent, Ghent, Belgium
5. Department of Microbiology and Infection Control, St. John’s General Hospital, Bruges, Belgium
6. Federal Agency for Medicines and Health Products, Brussels, Belgium
7. Department of Microbiology, Hôpital Erasme, Brussels, Belgium
8. Infectious Diseases Epidemiology, School of Public Health, Université Libre de Bruxelles, Brussels, Belgium

A Belgian Antibiotic Policy Coordination Committee (BAPCOC) was officially established in 1999 by Royal Decree. The overall objective of BAPCOC is to promote judicious use of antibiotics in humans and animals and to promote infection control and hospital hygiene, with the overall aim to reduce antibiotic resistance. BAPCOC fostered strong and interdisciplinary public health, scientific and political leadership, which led to many evidence-based interventions such as multimedia campaigns to promote the prudent use of antibiotics in the community, national campaigns to promote hand hygiene in hospitals, publication of clinical practice guidelines, staffing and technical support for establishment of antibiotic management teams in all Belgian hospitals, surveillance programmes on antibiotic use and resistance in humans and animals and the promotion of research. These activities and interventions resulted in a measurable decrease in antibiotic use and resistance in the community and hospitals.

Introduction

Belgium is a small federal country with 10.5 million inhabitants living in three regions. In 1999, the Belgian Ministry of Health established by Royal Decree an official committee, called the Belgian Antibiotic Policy Coordination Committee (BAPCOC) [1]. The specific objectives of BAPCOC are to promote judicious use of antibiotics in humans and animals and enhance infection control and hospital hygiene, with the overall aim of reducing antibiotic resistance.

The specific tasks of BAPCOC are to:
- collect information on antibiotic use and resistance to antibiotics in humans and animals;
- publish reports on the evolution of antibiotic use and resistance;
- create awareness of the evolution of antibiotic resistance and the risks for public health;
- publish recommendations on the detection and surveillance of antibiotic resistance, on the appropriate use of antibiotics, on indications for prophylactic and therapeutic use of antibiotics, on the evaluation and the surveillance of antibiotic use in humans and animals, and on the implementation of international recommendations on the prudent use of antibiotics in humans and animals;
- and to publish recommendations on future research into the emergence, spread and control of antibiotic resistance.

Table

<table>
<thead>
<tr>
<th>Activity</th>
<th>Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multimedia campaigns to promote the prudent use of antibiotics in the community</td>
<td>400,000 € per campaign</td>
</tr>
<tr>
<td>National campaigns to promote hand hygiene in hospitals</td>
<td>125,000 € per campaign</td>
</tr>
<tr>
<td>Staffing and technical support for establishment of antibiotic management teams in all Belgian hospitals</td>
<td>3.6 million € each year</td>
</tr>
<tr>
<td>Publication of clinical practice guidelines</td>
<td>25,000 € per guideline</td>
</tr>
<tr>
<td>Publication of guide to antibiotic prescribing in ambulatory care</td>
<td>100,000 € per guide</td>
</tr>
<tr>
<td>Surveillance programmes on antibiotic use and resistance in humans and animals</td>
<td>100,000 € each year</td>
</tr>
<tr>
<td>Promotion of research e.g.</td>
<td></td>
</tr>
<tr>
<td>- prevalence of MRSA among nursing home residents</td>
<td></td>
</tr>
<tr>
<td>- prevalence of MRSA ST398 in pigs and pig farmers</td>
<td></td>
</tr>
<tr>
<td>Support infection control practices (better funding and clear organisation in hospitals)</td>
<td>3.4 million € additional funding in 2007</td>
</tr>
</tbody>
</table>
To address these specific tasks, BAPCOC founded the following five multidisciplinary working groups: ambulatory care, hospital care, awareness campaigns, infection control and veterinary medicine. The working groups are composed of microbiologists, infectious diseases professionals, and infection control specialists, epidemiologists, general practitioners (GPs), pharmacists, nurses, veterinarians, basic researchers, public health experts, and health economists. The (scientific) secretariat, responsible for their day-to-day management, is hosted by the Federal Public Service Health, Food Chain Safety and Environment, Brussels, Belgium. A Steering Committee, composed of the presidents of the working groups, the chair and vice-chair of BAPCOC, meets monthly. The Steering Committee is responsible for the continuity, interaction, and follow-up of initiatives and projects. At plenary meetings of BAPCOC, which are held every four months, the working groups report on their activities so that all stakeholders, including policy makers, scientific organisations, and public health institutes are informed about the BAPCOC activities and results.

The key BAPCOC activities and corresponding budgets are listed in the Table. BAPCOC’s annual budget in 2007 was 7.8 million EUR. Furthermore, BAPCOC participates in European projects, such as European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be), European Antimicrobial Resistance Surveillance System (EARSS; www.rivm.nl/earss), ABS International (www.abs-international.eu), and e-bug (www.e-bug.eu).

This paper discusses selected examples of the activities and achievements of BAPCOC.

**Public antibiotic awareness campaigns**

The BAPCOC working group for public awareness campaigns set the following goals:

- to provide the general public with a better understanding of the natural course of minor and self-limiting infections, such as common cold, acute bronchitis, or influenza;
- to explain when the use of antibiotics is needed, i.e. in case of serious bacterial infections;
- to underline the consequences of emergence of resistance to antibiotics;
- and to facilitate a discussion between patients doctors and pharmacists on the need for appropriate antibiotic use.

No specific target for reductions in antibiotic sales was set.

In December 2000, BAPCOC launched a media campaign which ran over three consecutive winter seasons and concentrated on simple messages that were conveyed through booklets, handouts, posters, prime-time television and radio spots, and websites, like “Use antibiotics less frequently, but better”, “Save antibiotics, they may save your life”, and “Talk to your doctor, talk to your pharmacist” (www.red-antibiotica.org) [2, 3]. The involvement of GPs, paediatricians, pneumologists, ear, nose and throat specialists as well as of retail pharmacists was sought through personalised letters accompanied by campaign materials for presentation to patients. In November 2004, a new media campaign was launched, using the slogan “Antibiotics are ineffective for the common cold, acute bronchitis and flu”; this ran until last winter season (www.antibiotics-info.be). On 18 November 2008, a new media campaign will be launched to mark the European Antibiotic Awareness Day.

The impact of these activities has been evaluated through pre- and post-campaign face-to-face interviews with the public, post-campaign surveys of the GPs, records of antibiotic sales and prescriptions in the retail pharmacies, and evolution of antibiotic resistance among pathogens frequently affecting the community. Outpatient antibiotic use, expressed by the number of reimbursed packages per 1,000 inhabitants per day, decreased by 36% between the winter season 1997-8 and 2006-7 in Belgium (Figure 1) [4]. Penicillin, tetracycline and macrolide resistance in *Streptococcus pneumoniae* increased up to the year 2000, after which it decreased substantially (Figure 2). Similarly, macrolide resistance in *Streptococcus pyogenes* decreased dramatically from 17% in 2001 to 2% in 2007 (Figure 3).

**National hand hygiene campaigns**

BAPCOC has organised two countrywide campaigns – in 2005 and in 2007 – for the prevention of nosocomial infections by improving

---

**Figure 1**

Outpatient antibiotic use in packages per 1,000 inhabitants per day, Belgium, July 1997 to June 2007

<table>
<thead>
<tr>
<th>Year</th>
<th>Penicillin</th>
<th>Tetracycline</th>
<th>Macrolide</th>
<th>Other J01* classes</th>
</tr>
</thead>
<tbody>
<tr>
<td>00-01</td>
<td>2.9%</td>
<td>2.5%</td>
<td>0.8%</td>
<td>3.5%</td>
</tr>
<tr>
<td>01-02</td>
<td>2.6%</td>
<td>2.0%</td>
<td>1.0%</td>
<td>2.8%</td>
</tr>
<tr>
<td>02-03</td>
<td>2.6%</td>
<td>1.8%</td>
<td>0.9%</td>
<td>2.6%</td>
</tr>
<tr>
<td>03-04</td>
<td>2.7%</td>
<td>2.0%</td>
<td>0.9%</td>
<td>2.7%</td>
</tr>
<tr>
<td>04-05</td>
<td>2.4%</td>
<td>1.8%</td>
<td>0.9%</td>
<td>2.8%</td>
</tr>
<tr>
<td>05-06</td>
<td>2.3%</td>
<td>1.7%</td>
<td>0.8%</td>
<td>2.6%</td>
</tr>
<tr>
<td>06-07</td>
<td>2.3%</td>
<td>1.6%</td>
<td>0.8%</td>
<td>2.4%</td>
</tr>
</tbody>
</table>

*Anatomical Therapeutic Chemical (ATC) classification code

**Figure 2**

Penicillin, tetracycline, macrolide (erythromycin) and ofloxacine resistance in *Streptococcus pneumoniae*, Belgium, 1985-2007

Number of strains tested varied between 1,218 in 2002 and 1,744 in 2005. Source: National Reference Centre S. pneumoniae (University of Leuven)
hand hygiene compliance in Belgian hospitals. Key components of these campaigns were audit with performance feedback, reminders (posters), educational sessions for healthcare workers, promotion of alcohol-based hand rubs, and patient awareness (folders). Participation, on a voluntary basis, was excellent for both campaigns: 97% for acute care hospitals, 66% for long-term care hospitals and 63% for psychiatric hospitals. Overall compliance with hand hygiene (measured by direct observation) increased significantly from 49% to 69% for the first campaign and from 53% to 69% for the second campaign. The third campaign will be held in December of 2008.

Antibiotic Management Teams in hospitals

Since the 1990s, there has been a move in Belgian hospitals to establish multidisciplinary antibiotic management teams (AMT) to contain antibiotic resistance and improve antibiotic prescribing. The BAPCOC working group on hospital care developed an implementation plan for this strategy by mobilising federal funding for AMTs and antibiotic managers. In 2002, a pilot project started with a yearly budget of 0.93 million euros for hiring trained antibiotic managers in 37 hospitals, selected from 69 candidate hospitals for their expertise and experience with a local antibiotic stewardship programme. Based on successful activity reports of these pilot hospitals [5], the project was extended to 61 hospitals in 2006 by doubling the financial support to 1.83 million euros and since July 2007 to all acute care hospitals with an annual budget of 3.61 million euros. The AMTs will remain in the BAPCOC programme and their tasks have been defined by Royal Decree. BAPCOC provides scientific support to the participating hospitals by means of a dedicated training course, national study days, standardised evaluation of local progress reports and national surveillance of antibiotic consumption in hospitals. In the years 2002-7, over 600 hospital pharmacists and physicians participated in BAPCOC-supported interuniversity teaching courses in antibiotic management. National workshops were held twice to share good practices between hospital AMTs. Analysis of the recent reports of the 61 pilot phase hospitals clearly demonstrates general adoption of well-established quality improvement interventions, such as an antibiotic formulary, guidelines for prophylactic and therapeutic antibiotic use, regular analysis of local antibiotic consumption and resistance profiles, and increasing conductance of clinical audits and drug use evaluations. In a recent international survey of structural indicators of antibiotic stewardship programmes, Belgian hospitals scored high on average (3.75/5). The survey showed that 90% of hospitals had key structural resources and tools in place for effective antibiotic management and infection control [6].

The impact of these activities in hospital infection control and antibiotic stewardship is monitored through a newly developed surveillance of hospital-anti-infective drug consumption as well as by several longstanding surveillance schemes of nosocomial infection and multidrug resistant pathogens coordinated by the Scientific Institute of Public Health. These include methicillin-resistant *Staphylococcus aureus* (MRSA), extended spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae* and pathogenic *Clostridium difficile*. An example of encouraging results is the 35% relative reduction since 2004 in the incidence of nosocomial acquisition of MRSA among patients admitted to acute care hospitals [7].

**Publication of guidelines and a guide for appropriate use of antibiotics**

BAPCOC, in collaboration with scientific experts and organisations, produced evidence-based guidelines for the appropriate use of antibiotics in hospitals and ambulatory care for important infectious disease syndromes such as acute sore throat, otitis media, sinusitis, community-acquired pneumonia, uncomplicated and complicated urinary tract infections. All BAPCOC guidelines were disseminated free of charge to all relevant physicians (GPs and/or specialists) in Belgium. The guideline recommendations for ambulatory care were supplemented by conclusions of systematic literature reviews. BAPCOC also produced a booklet in 2004 on antibiotic treatment of community-acquired infectious diseases. All Belgian GPs received a copy of this first antibiotic booklet in 2004. A copy of the second edition of this antibiotic guide will be distributed among all primary care physicians in November 2008. The impact of this antibiotic guide for outpatients is monitored based on antibiotic prescribing in the community by indication, age and class of antibiotics.

**Surveillance programmes on antibiotic use and resistance in humans and animals**

BAPCOC provides support and additional funding for surveillance of MRSA, vancomycin-resistant enterococci (VRE), ESBL-producing *Enterobacteriaceae*, *S. pneumoniae* and *S. pyogenes*. BAPCOC also supports surveillance programmes on antibiotic use in hospitals, such as point prevalence surveys. The results of these surveillance programmes are published in an annual report, published by the Public Health Institute in Brussels.

**Research projects funded by BAPCOC**

BAPCOC funded a number of research projects to provide scientific evidence for national policies and guidelines of which examples are given below.

**National survey of prevalence of MRSA carriage among residents of nursing homes**

BAPCOC funded the first national survey of prevalence of MRSA carriage among residents of nursing homes in Belgium. The objectives of this survey were to study the national prevalence of MRSA colonisation in Belgian nursing home residents, to identify risk factors for MRSA carriage among nursing home residents, in respect of both the individual resident and of the nursing home population.

---

**Figure 3**

Macrolide (erythromycin) resistance in *Streptococcus pyogenes*, Belgium, 2002 to 2007

Number of strains tested varied between 1296 in 2002 and 934 in 2007. Source: National Reference Centre Streptococcus pyogenes (University of Antwerp).
Public and healthcare professionals and those interventions in
the general public health, scientific and political engagement in Belgium led
operative infection control.

The results are detailed in an advisory document reported to the
compliance with local and/or (inter)national precaution measures.

Clear demonstration of the extensive variability in infection control
precaution, and finally whether the respective items are written
standard operating procedure (SOP) for the performance for this
postoperative wound infections.

For each essential item, participants reported the estimated
degree of compliance in their institution, the existence of a
standard operating procedure (SOP) for the performance for this
precaution, and finally whether the respective items are written
down in institutional guidelines or procedures. The investigation
clearly demonstrated the extensive variability in infection control
practices in Belgian operating rooms, with respect to standards
architecture and structure, environmental cleaning, peri-operative
list of essential precautions was grouped into different categories:

- Evaluation of the extent to which internationally suggested infection
  control practices in operating rooms. More than half
  farmers is related to those in swine, to characterise and compare
  phenotypes and genotypes of MRSA strains from humans and
  and to study risk factors for MRSA colonisation and assess
  levels of personal hygiene in farm workers. Extensive colonisation
  with two subtypes of the livestock-associated ST398 MRSA strain
  was found in swine (44% carriers from 68% of farms) and farmers
  (38%) in contact with swine and other animals. Reported use of
  personal protection equipment and decontamination showed no
  difference in the rates of colonisation [8]. As a result of this survey,
  a National MRSA Med Vet Task Force was established to coordinate
  further investigation of the epidemiology of MRSA in animals and
  persons in contact with animals and to develop guidelines for risk
  management.

National investigation on the infection control practices in surgery
BAPCOC funded and supported a national investigation on infection
control practices in operating rooms. More than half
of all acute care hospitals participated in a national inventory
evaluating the extent to which internationally suggested infection
prevention precautions are defined, carried out and followed-up. A
list of essential precautions was grouped into different categories:
architecture and structure, environmental cleaning, peri-operative
procedures, sterilisation, logistic activities and surveillance of
postoperative wound infections.

Conclusions
Our experience demonstrates that strong joint and interdisciplinary
public health, scientific and political engagement in Belgium led
to many evidence-based interventions, aimed at both the general
public and healthcare professionals and those interventions in
return resulted in a decrease in antibiotic use and resistance in the
community and hospitals. They also show that creating awareness
for the factors driving antimicrobial resistance and providing a
knowledge base for physicians, public health experts and scientists
is crucial in containing antibiotic resistance. A number of scientific
conferences and public health workshops organised by BAPCOC
were helpful in this respect.

References
1. Royal Decree of April 26, 1999. Creation of Belgian Antibiotic Coordination
Association between antibiotic sales and public campaigns for their
4. Davey R, Ferech M, Anzarli F, Muller A, Goossens H, on behalf of the ESAC
Project Group. Outpatient antibiotic use in the four administrations of the
Sep 11 [Epub ahead of print].
5. Sourdeau L, Struelens MJ, Peetermans WE, Costers M, Suetens C. Hospital Care
Working Group of Belgian Antibiotic Policy Coordination Committee (BAPCOC).
Implementation of antibiotic management teams in Belgian hospitals. Acta
6. Struelens MJ, Costers M. Belgian Antibiotic Policy Coordination Committee
(BAPCOC) – Hospital Care Working Group.
7. Hospital antibiotic management in Belgium - results of the ABS maturity survey
8. Jans B, Struelens M. [Surveillance des MRSA dans les hôpitaux aux algar belges :
premier semestre 2007]. Surveillance of MRSA in acute-care Belgian hospitals:
prevalence of “livestock-associated” methicillin-resistant Staphylococcus
aureus ST398 in swine and pig farmers in Belgium. Inc Abstracts of the 18th
European Congress of Clinical Microbiology and Infectious Diseases, (ECCMID),

This article was published on 13 November 2008.
Citation style for this article: Goossens H, Coenen S, Costers M, De Corte S, De Sutter
A, Gorits B, Laurier L, Struelens MJ. Achievements of the Belgian Antibiotic Policy
Coordination Committee (BAPCOC), Euro Surveill. 2008;13(46):pii=19036. Available online:
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19036